Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms - Test2 - elhamkhani - TriplyDB

Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms

Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms

http://www.wikidata.org/entity/Q34021151

about

JAK2 Inhibition: Reviewing a New Therapeutical Option in Myeloproliferative Neoplasms Megakaryocyte pathology and bone marrow fibrosis: the lysyl oxidase connection Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib Therapeutic approaches in myelofibrosis and myelodysplastic/myeloproliferative overlap syndromes Circulating Cytokine Levels as Markers of Inflammation in Philadelphia Negative Myeloproliferative Neoplasms: Diagnostic and Prognostic Interest Inflammation as a Driver of Clonal Evolution in Myeloproliferative Neoplasm To Extinguish the Fire from Outside the Cell or to Shutdown the Gas Valve Inside? Novel Trends in Anti-Inflammatory Therapies Clinical potential of pacritinib in the treatment of myelofibrosis Targeting the tumor microenvironment: JAK-STAT3 signaling Targeting JAK2 in the therapy of myeloproliferative neoplasms Critical appraisal of the role of ruxolitinib in myeloproliferative neoplasm-associated myelofibrosis Advances in the management of myelofibrosis The evolving treatment paradigm in myelofibrosis Janus kinase inhibitors: jackpot or potluck?Aconitase regulation of erythropoiesis correlates with a novel licensing function in erythropoietin-induced ERK signaling.Identification of Novel Inhibitors of the Type I Interferon Induction Pathway Using Cell-Based High-Throughput Screening Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML Ruxolitinib in the treatment of polycythemia vera: patient selection and special considerations Targeted sequencing identifies associations between IL7R-JAK mutations and epigenetic modulators in T-cell acute lymphoblastic leukemia NF-κB-activating complex engaged in response to EGFR oncogene inhibition drives tumor cell survival and residual disease in lung cancer Emerging therapies for systemic lupus erythematosus--focus on targeting interferon-alpha Efficacy of NS-018, a potent and selective JAK2/Src inhibitor, in primary cells and mouse models of myeloproliferative neoplasms Heterozygous and homozygous JAK2(V617F) states modeled by induced pluripotent stem cells from myeloproliferative neoplasm patients c-Src binds to the cancer drug Ruxolitinib with an active conformation A Novel Triazolopyridine-Based Spleen Tyrosine Kinase Inhibitor That Arrests Joint Inflammation Functional Selectivity in Cytokine Signaling Revealed Through a Pathogenic EPO Mutation Targeting substrate-site in Jak2 kinase prevents emergence of genetic resistance Potential strategies for increasing drug-discovery productivity.Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.Ruxolitinib: a new JAK1/2 inhibitor that offers promising options for treatment of myelofibrosis.A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.Biology and clinical management of myeloproliferative neoplasms and development of the JAK inhibitor ruxolitinib Ruxolitinib, an oral JAK1 and JAK2 inhibitor, in myelofibrosis.Ruxolitinib: in the treatment of myelofibrosis.Emerging drugs for myelofibrosis.Ruxolitinib: a new treatment option for myelofibrosis.A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea.Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts Optimizing management of ruxolitinib in patients with myelofibrosis: the need for individualized dosing.Efficacy of ruxolitinib for myelofibrosis.

P2860

Q21285040-4CF24F36-F954-4B12-8200-0FDEDF8CF729 Q24607513-76068CCC-3ABF-467C-893B-9CBD684C535D Q26750696-630A87B2-24E7-4A93-B62C-3A762FA34627 Q26752940-0C95B29B-B3CC-4FC4-BBC1-402CA96B4653 Q26777398-A94D80CB-CADC-479D-B687-849A55EB717E Q26779936-570FC692-97BF-496C-88CA-87179186EECE Q26786973-94E865CE-AFC0-40CE-AD0B-D2FCED343FE6 Q26796450-1B7607A3-DDCD-4DE5-8B07-77426ADAE362 Q26825658-3A44103C-0725-4D39-B314-E0C2837A43E3 Q26860796-A1F7EF76-5ADB-49CD-A5B6-5A900014A983 Q26996258-B70ECF61-ACB4-419D-8533-B8D5B135F681 Q27008072-BEE45F3B-F500-491E-AE72-465F383B03CC Q27021968-E146B4F1-EEAB-4EAC-B698-B55A21EB725B Q27027230-E704D38E-68F8-4AE2-AF84-2672DDA6DD54 Q27323049-1E2F8B2B-D6E2-4FF3-ABD1-AF9C0490FB26 Q27469008-C062AB28-2948-470E-8610-05C706E0BA0E Q27852275-A238C543-D61F-4855-840C-05B9917BA4EE Q28078404-E54C1579-6279-4289-BDDE-E29E7382B841 Q28112138-19F143D4-CA48-4A20-B36E-9A8B97BA2219 Q28259999-4C95A2E1-ED7E-49DF-A7E0-69F29555B5BB Q28265144-32A3984D-1766-486F-AEB6-50B41E38FBFA Q28271752-5856ADDE-EFCF-4586-B4DC-3345149525AD Q28533511-6AAE7778-AC80-44D9-9EA7-38C47E519D6E Q28542851-1742F071-ECAA-4420-BBDA-956EE32F1497 Q28552367-AE31D964-9234-432F-A372-F66267B0FEB9 Q29147543-8821FF92-131C-4CDD-AB30-E0037D92D847 Q30666276-F5DEB333-55DB-4DC9-9E36-30896208D311 Q31154360-2BFC9E66-E77B-4CDF-B0D3-A06F8255D2DB Q33391880-F07A471B-03DA-4E71-95AB-8CB0379A3F31 Q33397219-C1BFBCC8-5ABC-4D34-AB0A-7925F752593E Q33399980-14CB9A00-E744-4983-A750-688AAD24BB83 Q33402522-EA4B2703-29D7-482A-B4BF-7E6D06CD7EEE Q33403735-BF650E28-9B4E-424E-A984-A59BF4AC8576 Q33403784-4A982ACC-0A73-4063-ACFB-24FAA76FCBDC Q33404574-9F879E44-333A-4511-9669-D13DB719200A Q33405241-422BFF8A-E12C-4E39-BBBA-A154EA538A95 Q33411637-F1895DF2-75D0-431A-A245-96263ED3E4EE Q33411755-2364B34C-B101-4DE1-99B0-FFD9A55F2BCB Q33411763-07C00549-8627-4079-AB87-8A9400761B1A Q33415489-2DBC5721-C822-46E2-93CA-959076A4A9BC

P2860

Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms

http://www.wikidata.org/entity/Q34021151

description

2010 nî lūn-bûn

@nan

2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Preclinical characterization o ...... f myeloproliferative neoplasms

@ast

Preclinical characterization o ...... f myeloproliferative neoplasms

@en

Preclinical characterization o ...... f myeloproliferative neoplasms

@nl

type

label

Preclinical characterization o ...... f myeloproliferative neoplasms

@ast

Preclinical characterization o ...... f myeloproliferative neoplasms

@en

Preclinical characterization o ...... f myeloproliferative neoplasms

@nl

prefLabel

Preclinical characterization o ...... f myeloproliferative neoplasms

@ast

Preclinical characterization o ...... f myeloproliferative neoplasms

@en

Preclinical characterization o ...... f myeloproliferative neoplasms

@nl

P1433

Q34021151-CA49D12F-C407-4A95-8C47-669570C3419E

P1476

Q34021151-1EE737C3-E479-4CDF-8FA4-B7DF0CDEC6D1

P2093

Q34021151-0528A28D-293E-49D8-BC52-69143038C32C

Q34021151-05720E73-180B-4E93-9DE2-A6F002C74C2D

Q34021151-154F2EF9-0C46-40B1-84C1-B53967DA819B

Q34021151-17DF6574-F7FF-4A81-A03D-C94BD5121F59

Q34021151-37B73A58-C9FE-4041-B8EC-A6C039BF07EF

Q34021151-5D5556AC-4B99-4CC4-B0A5-1B85261954C4

Q34021151-6AF52FF3-CA71-4FA6-B199-E5A9A3E55075

Q34021151-6EED0ADE-8626-48A7-95DE-35334A2DD25E

Q34021151-8205B5E1-2A77-4DA6-B618-C7568E964ACF

Q34021151-8D7856EE-8F86-490B-BDB6-8F1C6A9009FB

P2860

Q34021151-000EE777-6BE5-443A-9CE0-C1FDDA53929B

Q34021151-046F7B4A-E53A-4879-94DC-0DF3A26B006A

Q34021151-0F0915D0-1826-40A7-B107-31D8680E02C6

Q34021151-1002EFCB-A03D-4404-AC8C-070257A20517

Q34021151-294142A4-1793-4310-9E81-68FE75B7E1D0

Q34021151-2E029176-B543-46AD-8246-02A28D92BA01

Q34021151-319FDDFE-9A78-4E0B-A77F-F7D191F7887C

Q34021151-63DF33FC-B32C-4479-BB11-236324902740

Q34021151-64F8C6E5-1587-4BAE-A259-25B7F5D14D2A

Q34021151-656D077A-97A9-41C6-AF13-A28CF7F6F0C5

P304

Q34021151-85AB81C4-7CAD-43AC-B546-FC56FFA4D220

P31

Q34021151-2E2AB8AC-BC41-4F42-857A-CEEA5E27EB8D

P356

Q34021151-B8CF4425-21B2-4849-9510-A9EF099126FC

P407

Q34021151-FA9D5925-FBBB-47B3-B961-A4399D485ADB

P433

Q34021151-ED139507-4D28-4F14-94F1-BAEB73F422A2

P478

Q34021151-E85FB4E0-BF7D-4E41-8F6B-EA254E0A8D94

P50

Q34021151-52F80629-C654-48A1-AC80-2B609EB139C5

Q34021151-89B7F15B-965B-404C-AB94-39D102356883

P577

Q34021151-E6353E8B-57D4-48DF-AD9D-1F6614A372C3

P5875

Q34021151-7FE50260-A049-4B57-AAD9-C7D9A21A08C4

P698

Q34021151-7CCD19DE-D04C-49EA-824F-F511FBBA7662

P932

Q34021151-79F10E5E-2D73-4DD8-B36B-8903731627B1

P356

BLOOD-2009-04-214957

P1433

P1476

Preclinical characterization o ...... f myeloproliferative neoplasms

@en

P2093

Alfonso Quintás-Cardama

http://www.w3.org/2001/XMLSchema#string

Eian Caulder

http://www.w3.org/2001/XMLSchema#string

James D Rodgers

http://www.w3.org/2001/XMLSchema#string

Jennifer Kelley

http://www.w3.org/2001/XMLSchema#string

Jordan S Fridman

http://www.w3.org/2001/XMLSchema#string

Jun Li

http://www.w3.org/2001/XMLSchema#string

Kris Vaddi

http://www.w3.org/2001/XMLSchema#string

Mark Rupar

http://www.w3.org/2001/XMLSchema#string

Maryanne Covington

http://www.w3.org/2001/XMLSchema#string

Patrick Haley

http://www.w3.org/2001/XMLSchema#string

P2860

Therapeutic targeting of Janus kinases

Transformation of hematopoietic cells and activation of JAK2-V617F by IL-27R, a component of a heterodimeric type I cytokine receptor

A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis

A gain-of-function mutation of JAK2 in myeloproliferative disorders

Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders

JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis.

Identification of an acquired JAK2 mutation in polycythemia vera.

Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation.

Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development.

P304

3109-3117

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2009-04-214957

http://www.w3.org/2001/XMLSchema#string

P407

P433

15

http://www.w3.org/2001/XMLSchema#string

P478

115

http://www.w3.org/2001/XMLSchema#string

P50

Hagop Kantarjian

Srdan Verstovsek

P577

2010-02-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

41405181

http://www.w3.org/2001/XMLSchema#string

P698

20130243

http://www.w3.org/2001/XMLSchema#string

P932

3953826

http://www.w3.org/2001/XMLSchema#string